Form 4: REGENXBIO Director Daniel Tasse Receives Significant Equity Awards

REGENXBIO Inc. Director Daniel Tasse was granted 7,768 restricted stock units and 39,815 stock options as part of his compensation, aligning his interests with long-term company performance.

Summary

• Daniel Tasse, a Director at REGENXBIO Inc. (RGNX), reported changes in his beneficial ownership of company securities.
• On May 30, 2025, Mr. Tasse acquired 7,768 shares of common stock through a time-based restricted stock unit (RSU) award.
• These RSU shares were granted at a price of $0.00 and will fully vest on May 1, 2026, contingent on his continuous service to the Issuer.
• Following this RSU grant, Mr. Tasse beneficially owns 19,054 shares of common stock.
• Additionally, on May 30, 2025, Mr. Tasse was granted 39,815 stock options with an exercise price of $8.85 per share.
• These stock options will vest in 12 equal monthly installments starting from May 30, 2025, also subject to his continuous service.
• The stock options have an expiration date of May 30, 2035, and were granted at a price of $0.00.
• After this transaction, Mr. Tasse beneficially owns 39,815 stock options.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While a routine compensation grant, it signifies continued commitment from a director and aligns their interests with the company's long-term success. There are no negative financial implications beyond minor potential dilution, which is standard for equity compensation.

Positives

• The grant of restricted stock units and stock options to Director Daniel Tasse aligns his financial interests with the long-term performance and growth of REGENXBIO Inc.
• Equity compensation at a $0.00 grant price for RSUs and options is a common practice for incentivizing directors and retaining talent.

Negatives

• The issuance of new equity awards, while standard for compensation, can lead to a minor dilutive effect on existing shareholders over time as shares vest and options are exercised.

Risks

• The vesting of both the restricted stock units and stock options is contingent upon Daniel Tasse's continuous service to REGENXBIO Inc., meaning the awards could be forfeited if his service terminates before vesting is complete.

Future Outlook

The vesting schedules for both the restricted stock units (May 1, 2026) and stock options (12 equal monthly installments from May 30, 2025) indicate a future alignment of the director's incentives with the company's performance over the coming year and beyond, contingent on his continued service.

Management Comments

• The filing indicates that the transactions were made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Industry Context

This Form 4 filing is a routine disclosure of insider equity compensation, common across all industries, including the biotechnology sector where REGENXBIO operates. Such grants are standard practice for attracting and retaining executive and board talent, aligning their long-term interests with shareholder value creation in a highly competitive industry.

Comparison to Industry Standards

• The grant of restricted stock units and stock options as part of director compensation is a standard practice in the biotechnology and pharmaceutical industries, comparable to compensation structures seen at companies like Sarepta Therapeutics (SRPT) or Alnylam Pharmaceuticals (ALNY), which also utilize equity awards to incentivize long-term commitment and performance.
• The vesting schedules (time-based for RSUs and monthly for options) are typical for such awards, designed to retain talent over a specified period, similar to compensation plans observed at other publicly traded biotech firms.

Corporate Governance

Related Party Transactions

• The grant of 7,768 restricted stock units and 39,815 stock options to Daniel Tasse, a Director of REGENXBIO Inc., constitutes a related party transaction as it involves the company providing compensation to an insider.

Stakeholder Impact

• Shareholders: The grants align the director's interests with shareholder value creation, but also represent potential future dilution upon vesting and exercise.
• Employees: While not directly impacting general employees, the compensation structure for directors can reflect the company's overall approach to incentivizing key personnel.
• Director (Daniel Tasse): Receives significant equity compensation, increasing his stake and potential future wealth tied to the company's performance.

Next Steps

• Monitoring the vesting of the 7,768 restricted stock units on May 1, 2026.
• Monitoring the monthly vesting of the 39,815 stock options commencing May 30, 2025.

Key Dates

Keywords

REGENXBIO, RGNX, Form 4, SEC filing, insider transaction, beneficial ownership, restricted stock units, RSU, stock options, equity compensation, director compensation, vesting, biotechnology, pharmaceuticals